Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of $187.44 billion. The enterprise value is $208.81 billion.
| Market Cap | 187.44B |
| Enterprise Value | 208.81B |
Important Dates
The next estimated earnings date is Thursday, October 29, 2026, after market close.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | Sep 15, 2026 |
Share Statistics
Gilead Sciences has 1.24 billion shares outstanding. The number of shares has decreased by -1.39% in one year.
| Current Share Class | 1.24B |
| Shares Outstanding | 1.24B |
| Shares Change (YoY) | -1.39% |
| Shares Change (QoQ) | -0.88% |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 91.16% |
| Float | 1.24B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 16.52 |
| PS Ratio | 6.15 |
| Forward PS | 5.95 |
| PB Ratio | 15.86 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.48 |
| P/OCF Ratio | 13.83 |
| PEG Ratio | 2.56 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.30, with an EV/FCF ratio of 16.13.
| EV / Earnings | n/a |
| EV / Sales | 6.86 |
| EV / EBITDA | 14.30 |
| EV / EBIT | 17.63 |
| EV / FCF | 16.13 |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 2.23.
| Current Ratio | 1.27 |
| Quick Ratio | 0.90 |
| Debt / Equity | 2.23 |
| Debt / EBITDA | 1.78 |
| Debt / FCF | 2.03 |
| Interest Coverage | 11.86 |
Financial Efficiency
Return on equity (ROE) is -20.68% and return on invested capital (ROIC) is 34.37%.
| Return on Equity (ROE) | -20.68% |
| Return on Assets (ROA) | 14.09% |
| Return on Invested Capital (ROIC) | 34.37% |
| Return on Capital Employed (ROCE) | 30.88% |
| Weighted Average Cost of Capital (WACC) | 5.70% |
| Revenue Per Employee | $1.79M |
| Profits Per Employee | -$190,588 |
| Employee Count | 17,000 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 3.29 |
Taxes
In the past 12 months, Gilead Sciences has paid $1.29 billion in taxes.
| Income Tax | 1.29B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +27.84% in the last 52 weeks. The beta is 0.33, so Gilead Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +27.84% |
| 50-Day Moving Average | 144.71 |
| 200-Day Moving Average | 137.32 |
| Relative Strength Index (RSI) | 59.00 |
| Average Volume (20 Days) | 5,754,497 |
Short Selling Information
The latest short interest is 21.83 million, so 1.76% of the outstanding shares have been sold short.
| Short Interest | 21.83M |
| Short Previous Month | 18.30M |
| Short % of Shares Out | 1.76% |
| Short % of Float | 1.76% |
| Short Ratio (days to cover) | 3.70 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of $30.46 billion and -$3.24 billion in losses. Loss per share was -$2.61.
| Revenue | 30.46B |
| Gross Profit | 24.25B |
| Operating Income | 11.84B |
| Pretax Income | -1.96B |
| Net Income | -3.24B |
| EBITDA | 14.60B |
| EBIT | 11.84B |
| Loss Per Share | -$2.61 |
Balance Sheet
The company has $4.88 billion in cash and $26.25 billion in debt, with a net cash position of -$21.36 billion or -$17.23 per share.
| Cash & Cash Equivalents | 4.88B |
| Total Debt | 26.25B |
| Net Cash | -21.36B |
| Net Cash Per Share | -$17.23 |
| Equity (Book Value) | 11.75B |
| Book Value Per Share | 9.53 |
| Working Capital | 2.93B |
Cash Flow
In the last 12 months, operating cash flow was $13.55 billion and capital expenditures -$609.00 million, giving a free cash flow of $12.94 billion.
| Operating Cash Flow | 13.55B |
| Capital Expenditures | -609.00M |
| Depreciation & Amortization | 2.76B |
| Net Borrowing | 1.29B |
| Free Cash Flow | 12.94B |
| FCF Per Share | $10.44 |
Margins
Gross margin is 79.60%, with operating and profit margins of 38.88% and -10.64%.
| Gross Margin | 79.60% |
| Operating Margin | 38.88% |
| Pretax Margin | -6.42% |
| Profit Margin | -10.64% |
| EBITDA Margin | 47.94% |
| EBIT Margin | 38.88% |
| FCF Margin | 42.50% |
Dividends & Yields
This stock pays an annual dividend of $3.28, which amounts to a dividend yield of 2.17%.
| Dividend Per Share | $3.28 |
| Dividend Yield | 2.17% |
| Dividend Growth (YoY) | 3.50% |
| Years of Dividend Growth | 10 |
| Payout Ratio | n/a |
| FCF Payout Ratio | 31.42% |
| Buyback Yield | 1.39% |
| Shareholder Yield | 3.56% |
| Earnings Yield | -1.73% |
| FCF Yield | 6.90% |
Analyst Forecast
The average price target for Gilead Sciences is $159.38, which is 5.43% higher than the current price. The consensus rating is "Buy".
| Price Target | $159.38 |
| Price Target Difference | 5.43% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 5.35% |
| EPS Growth Forecast (3Y) | 9.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 28, 2013. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 28, 2013 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Gilead Sciences has an Altman Z-Score of 4.05 and a Piotroski F-Score of 5.
| Altman Z-Score | 4.05 |
| Piotroski F-Score | 5 |